A simple sugar sold to prevent recurrent urinary tract infections — early trials were encouraging, but a larger 2024 trial found no benefit.
What the evidence supports: UTI prevention — early small trials were positive, a larger 2024 trial was not.
This scores how well-supported the claim above is — not how much benefit you personally would get. A high score on a narrow claim does not extend to everything the product is marketed for.
Ongoing for prevention if used — but the best-quality evidence now questions its benefit.
Women with recurrent UTIs exploring options, with realistic expectations.
No commonly documented medication clashes in our data. That is not the same as none existing.
Run your full list through the interaction check.